• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

作者信息

Jia Ertao, Yan Guangyao, Xiao Min, Geng Hongling, Wei Jiaxin, Zhang Jianyong

机构信息

The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China.

The Department of Gynecology, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China.

出版信息

Dermatol Ther. 2020 Nov;33(6):e14470. doi: 10.1111/dth.14470. Epub 2020 Nov 16.

DOI:10.1111/dth.14470
PMID:33112475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7816240/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/7816240/5f620bc0e9ea/DTH-33-e14470-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/7816240/d6bdb360d82f/DTH-33-e14470-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/7816240/8147126166c4/DTH-33-e14470-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/7816240/5f620bc0e9ea/DTH-33-e14470-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/7816240/d6bdb360d82f/DTH-33-e14470-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/7816240/8147126166c4/DTH-33-e14470-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/7816240/5f620bc0e9ea/DTH-33-e14470-g003.jpg

相似文献

1
Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.托法替布成功治疗与类脂质渐进性坏死性血管病相关的难治性溃疡
Dermatol Ther. 2020 Nov;33(6):e14470. doi: 10.1111/dth.14470. Epub 2020 Nov 16.
2
Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.托法替布可缓解由TMEM173基因的2个新发变异导致的婴儿期起病的干扰素基因刺激物（STING）相关血管病的症状。
J Allergy Clin Immunol. 2017 Apr;139(4):1396-1399.e12. doi: 10.1016/j.jaci.2016.10.030. Epub 2016 Dec 29.
3
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.带状疱疹作为与托法替布相关的非典型慢性溃疡的一个病因。
Dermatol Online J. 2018 Jan 15;24(1):13030/qt3v77g2zg.
4
Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.新型低剂量口服抗凝剂治疗顽固性类脂质渐进性坏死性血管病的疗效
BMJ Case Rep. 2017 Jul 24;2017:bcr-2017-219943. doi: 10.1136/bcr-2017-219943.
5
A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.一例大动脉炎合并难治性溃疡性结肠炎患者经托法替布治疗成功
Rheumatology (Oxford). 2020 Jul 1;59(7):1773-1775. doi: 10.1093/rheumatology/kez580.
6
Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.皮肤梗死的 livedoid 血管病变 - 目前的诊断和治疗方面。
J Dtsch Dermatol Ges. 2013 May;11(5):407-10. doi: 10.1111/ddg.12064. Epub 2013 Feb 26.
7
[Vasculitis and vasculopathy].[血管炎与血管病]
Acta Med Croatica. 2012 Oct;66 Suppl 1:19-24.
8
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.托法替尼改善狼疮小鼠及其相关血管功能障碍。
Arthritis Rheumatol. 2017 Jan;69(1):148-160. doi: 10.1002/art.39818.
9
Dabigatran in the management of livedoid vasculopathy.达比加群酯在治疗类脂质渐进性坏死中的应用
Clin Exp Dermatol. 2017 Mar;42(2):237-239. doi: 10.1111/ced.13022. Epub 2017 Jan 4.
10
Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin.伴有血栓前状态的类脂质渐进性坏死性血管病所致溃疡：对华法林的反应
J Am Acad Dermatol. 2008 Mar;58(3):512-5. doi: 10.1016/j.jaad.2006.04.087.

引用本文的文献

1
Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report.用Janus激酶抑制剂托法替布治疗难治性节段性透明血管炎：一例报告
Clin Cosmet Investig Dermatol. 2025 Jun 12;18:1453-1457. doi: 10.2147/CCID.S530188. eCollection 2025.
2
Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib.口服托法替布有效治疗类癌性血管病
Clin Case Rep. 2025 May 28;13(6):e70536. doi: 10.1002/ccr3.70536. eCollection 2025 Jun.
3
A case report and literature review of livedoid vasculopathy in children.

本文引用的文献

1
Targeting JAK/STAT pathway in Takayasu's arteritis.靶向大动脉炎中的 JAK/STAT 通路。
Ann Rheum Dis. 2020 Jul;79(7):951-959. doi: 10.1136/annrheumdis-2019-216900. Epub 2020 Mar 25.
2
Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.抗 TNF-α 药物治疗难治性结节性红斑样血管炎的疗效：回顾性分析。
J Dermatolog Treat. 2022 Feb;33(1):178-183. doi: 10.1080/09546634.2020.1737634. Epub 2020 Mar 9.
3
Livedoid vasculopathy presenting with leg ulcers.以腿部溃疡为表现的萎缩性硬化性苔藓样血管病。
儿童类脂质渐进性坏死性血管病的病例报告及文献综述
Front Pediatr. 2025 May 14;13:1537133. doi: 10.3389/fped.2025.1537133. eCollection 2025.
4
Livedoid vasculopathy, calciphylaxis, and Martorell's hypertensive ulcer: update on ischemic ulcers due to impaired microcirculation of the lower limbs.萎缩性硬化性苔藓样血管病、钙化防御和马托雷尔高血压性溃疡：下肢微循环障碍所致缺血性溃疡的最新进展。
An Bras Dermatol. 2025 Mar-Apr;100(2):215-227. doi: 10.1016/j.abd.2024.09.004. Epub 2025 Jan 22.
5
Pain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.萎缩性紫癜性血管病合并周围神经病变患者的疼痛管理方案
Eur J Case Rep Intern Med. 2023 Jan 30;10(1):003727. doi: 10.12890/2023_003727. eCollection 2023.
6
Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.巴瑞替尼可能对治疗难治性类脂蛋白血管病变有效。
Front Immunol. 2022 Oct 27;13:1008392. doi: 10.3389/fimmu.2022.1008392. eCollection 2022.
7
Livedoid vasculopathy: A review with focus on terminology and pathogenesis.皮肤白细胞碎裂性血管病：术语和发病机制综述。
Vasc Med. 2022 Dec;27(6):593-603. doi: 10.1177/1358863X221130380. Epub 2022 Oct 26.
8
Livedoid vasculopathy - A diagnostic and therapeutic challenge.萎缩性硬化性苔藓样血管病——诊断与治疗的挑战。
Front Med (Lausanne). 2022 Oct 3;9:1012178. doi: 10.3389/fmed.2022.1012178. eCollection 2022.
9
Adalimumab in Treating Refractory Livedoid Vasculopathy.阿达木单抗治疗难治性萎缩性硬化性苔藓样血管炎
Vaccines (Basel). 2022 Apr 1;10(4):549. doi: 10.3390/vaccines10040549.
Rheumatology (Oxford). 2019 Nov 1;58(11):2076. doi: 10.1093/rheumatology/kez126.
4
Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.皮肤白细胞碎裂性血管病：法国观察性研究包括治疗选择。
Acta Derm Venereol. 2018 Oct 10;98(9):842-847. doi: 10.2340/00015555-2965.
5
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.JAK-STAT 信号抑制在大中血管血管炎中的致病性免疫反应。
Circulation. 2018 May 1;137(18):1934-1948. doi: 10.1161/CIRCULATIONAHA.117.030423. Epub 2017 Dec 18.
6
Three cases of lymphocytic thrombophilic arteritis presenting with an annular eruption.三例淋巴细胞性血栓形成性动脉炎伴环状皮疹。
Australas J Dermatol. 2018 May;59(2):e127-e132. doi: 10.1111/ajd.12679. Epub 2017 Jul 28.
7
Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.与凝血酶原G20210A和因子V（莱顿）杂合性以及亚甲基四氢叶酸还原酶C677T纯合性相关的萎缩性硬化性苔藓样血管病
J Thromb Thrombolysis. 2008 Aug;26(1):31-4. doi: 10.1007/s11239-008-0214-1. Epub 2008 Mar 23.
8
Series introduction. JAK-STAT signaling in human disease.系列介绍。人类疾病中的JAK-STAT信号传导。
J Clin Invest. 2002 May;109(9):1133-7. doi: 10.1172/JCI15644.
9
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.2002年的细胞因子信号传导：Jak/Stat途径中的新惊喜。
Cell. 2002 Apr;109 Suppl:S121-31. doi: 10.1016/s0092-8674(02)00701-8.